Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-545-4 | CAS number: 7631-86-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
Materials and methods
- Study type:
- study with volunteers
- Endpoint addressed:
- repeated dose toxicity: oral
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Syloid HC was administered with the morning and evening feeding, starting with an oral dose of 1.0 gram per day that increased by 1.0 g daily up to a final, dose of 16 g/day. Syloid HC was given in two equally divided doses with the morning and evening feeding, to determine whether oral ingestion of silica hydrogel (Syloid 701) lowers significantly the levels of plasma total and low density (beta) lipoprotein (IDL) cholesterol in patients with primary type IIa hyperlipoproteinemia.
- GLP compliance:
- no
Test material
- Reference substance name:
- Silicon dioxide
- EC Number:
- 231-545-4
- EC Name:
- Silicon dioxide
- Cas Number:
- 7631-86-9
- Molecular formula:
- O2Si
- IUPAC Name:
- dioxosilane
- Test material form:
- solid: nanoform
Constituent 1
- Specific details on test material used for the study:
- Syloid HC (701)
Method
- Type of population:
- general
- Subjects:
- Six adult patients (three men and three nonpregnant women) with primary type Ila hyperlipoproteinemia (plasma LDL cholesterol level above age and sex specific 95th%; normal plasma total triglyceride level; no floating beta lipoproteins present from the Johns Hopkins Lipid Clinic were admitted to the Clinical Research Unit for three weeks. They were on no lipid-lowering or other medication for at least three weeks prior to admission.
- Ethical approval:
- not specified
- Route of exposure:
- oral
- Reason of exposure:
- intentional
- Exposure assessment:
- measured
- Details on exposure:
- The short-term safety and efficacy of Syloid HC was studied in six adults (aged 20 to 51 years) with primary type II hyperlipoproteinemia. Three men and three women were admitted to a metabolic unit for three weeks. Four subjects were studied on a liquid formula diet containing 100 mg cholesterol/day and a ratio of polyunsaturated to saturated fat (P/S) of 1.0, while the other two were ingesting.a solid food diet containing 200 mg cholesterol/day a.hd a P/S of 2.0. Sufficient calories were provided to keep the weight constant {+ 1 kg). Syloid HC was administered with the morning and evening feeding, starting with an oral dose of 1.0 gram per day that increased by 1.0 g daily up to a final, dose of 16 gm/day. Syloid HC was given in two equally divided doses with the morning and evening feeding.
- Examinations:
- Specific Objectives
To determine whether oral ingestion of silica hydrogel (Syloid 701) lowers significantly the levels of plasma total and low density (beta) lipoprotein (IDL) cholesterol in patients with primary type IIa hyperlipoproteinemia.
2. To determine, through a dose-response study, the optimal dose of the silica hydrogel that lowers plasma total and LDL cholesterol.
3. To determine to what extent, if any, silica hydrogel is absorbed from the intestinal tract into the bloodstream.
4. To assess short-term clinical and chemical side effects of silica gel in these patients.
5. To determine the effect of silica gel on sterol metabolism; specifically, cholesterol synthesis and the excretion in the stool of neutral sterols and bile acids.
Results and discussion
- Clinical signs:
- In one subject, bile acid excretion increased somewhat but not markedly so.
- Results of examinations:
- No statistically significant effect of Syloid HC on the plasma levels of total cholesterol, low density (beta) lipoprotein.(LDL) cholesterol, high density (alpha) lipoprotein (HDL) cholesterol or total triglycerides was found. There was no significant increase in the serum or urinary levels of silica after Syloid HC administration.
Any other information on results incl. tables
As judged by clinical and chemical criteria, no significant adverse effects of Syloid HC were observed on hepatic or renal function. The number of white and red blood cells and platelets were unaffected. Two subjects had a fall in serum iron levels, one a fall in hemoglobin concentration, two had falls in carotene, one a fall in serum folate and another a fall in the vitamin A level. Clinical side effects include constipation in half the subjects, an unusual aftertaste in all 6, and one patient suffered gastritis.
Applicant's summary and conclusion
- Conclusions:
- In doses of up to 16 gm/day Syloid HC did not have a significant effect on the plasma lipid and lipoprotein levels in subjects with primary type II hyperlipoproteinemia. Although only slight untoward side effects were observed, however, at higher doses, Syloid HC is unpleasant to take and produces constipation.
- Executive summary:
The short-term safety and efficacy of Syloid HC (a.k.a. Syloid 701) was studied in six adults with primary type II hyperlipoproteinemia.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.